BRKRHealthcare · Medical DevicesThe 13 Wall Street analysts covering Bruker Corp. hold a median 12-month price target of $65 — +16.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Bruker Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (89): The share count has been shrinking and the company is not leaning on new borrowing.
Revisions (57): Analysts have, on balance, been cutting their forecasts.
Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BRKR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +16.0% from it.
Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | TD Cowen | Maintains | Hold | $60 → $62 |
| 7 Oct 2026 | Barclays | Maintains | Overweight | $58 → $70 |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | $70 → $72 |
| 29 Sept 2026 | Leerink Partners | Maintains | Outperform | $60 → $80 |
| 29 Sept 2026 | Leerink Partners | Maintains | Outperform | — |
| 9 Sept 2026 | UBS | Maintains | Neutral | $45 → $65 |
| 9 Sept 2026 | UBS | Maintains | Neutral | — |
| 5 Aug 2026 | Citigroup | Maintains | Neutral | — |
| 5 Aug 2026 | Citigroup | Maintains | Neutral | $60 → $53 |
| 8 July 2026 | Citigroup | Maintains | Neutral | — |
| 8 July 2026 | Citigroup | Maintains | Neutral | $44 → $60 |
| 7 July 2026 | Leerink Partners | Maintains | Outperform | $60 → $70 |
| 7 July 2026 | Leerink Partners | Maintains | Outperform | — |
| 29 June 2026 | Guggenheim | Maintains | Buy | — |
| 24 June 2026 | Barclays | Maintains | Overweight | — |
| 8 June 2026 | JP Morgan | Maintains | Overweight | — |
| 2 June 2026 | Wolfe Research | Assumes | Peer Perform | — |
| 7 May 2026 | Barclays | Maintains | Overweight | — |
| 7 May 2026 | Citigroup | Maintains | Neutral | — |
| 7 May 2026 | TD Cowen | Maintains | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BRKR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Bruker Corp. returned +52.9% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 9% of US stocks
Cheaper than 46% of US stocks
Cheaper than 26% of US stocks
Cheaper than 16% of US stocks
Higher than 39% of US stocks
Higher than 42% of US stocks
Higher than 61% of US stocks
Higher than 64% of US stocks
Higher than 27% of US stocks
Higher than 41% of US stocks
Higher than 66% of US stocks
Higher than 64% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bruker Corp. has a market value of $8.6B and an enterprise value of $10.3B.
Revenue in the twelve months to 30 June 2026: $3.5B. The latest quarter grew 5.2% year on year.
Net income over the same four quarters: −$64.5M, a −1.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.70.
Free cash flow in the twelve months to 30 June 2026: $64.5M.
Bruker Corp. spent $54.7M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 74.9×; forward P/E: 23.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.36%, paying out 38% of earnings.
Bruker Corp. employs 11,085 people — $316K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Bruker Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Bruker shares gained 66.3% over a year, supported by strong demand in mass spectrometry and biopharma, despite restructuring challenges and currency headwinds.
Why it matters — The item highlights the demand drivers behind BRKR's share gain alongside operational and currency challenges.
Bruker announced a bioRxiv preprint describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution. The study was conducted by Markus Ralser at Charité – Universitätsmedizin Berlin and collaborators.
Why it matters — The announcement highlights research involving Bruker and discovery of the plasma proteome at proteoform resolution.
Zacks Investment Research has highlighted Bruker (BRKR) as a top momentum stock for the long term, citing its strong stock characteristics. The article points to the Zacks Style Scores, a feature of the Zacks Premium research service, as a tool that helps investors identify stocks like Bruker.
Why it matters — BRKR watchers would care because Bruker is being recognized by Zacks as a strong momentum pick for long-term investors, signaling potential positive attention from the research community.
At the Human Proteome Organization World Congress 2026, Bruker announced new timsUltra AIP and timsOmni workflows for functional proteomics, covering protein-sequence coverage, targeted validation, glycopeptide characterization, structural proteomics, and oligonucleotide analysis, along with multi-enzyme dia-PASEF and ProteoScape workflows.
Why it matters — These new proteomics workflows expand Bruker's product portfolio for drug discovery and disease biology research, potentially broadening its market reach among researchers.
Bruker CFO Gerald Herman said second-quarter results reflected stronger-than-expected organic order bookings and earnings per share, though revenue came in later than anticipated. He attributed the timing to a mixed demand environment and shipment timing, including semiconductor-metrology orders expected to shift into the fourth quarter.
Why it matters — BRKR watchers would note that semiconductor-metrology orders being pushed to Q4 will affect near-term revenue timing and the company's expected fourth-quarter rebound.
The 13 Wall Street analysts covering Bruker Corp. have a median 12-month price target of $65, with estimates ranging from $50 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Bruker Corp., 7 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bruker Corp. 86 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Bruker Corp. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (89 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +16.0% from the last close, and Ticker Nerd's factor model ranks Bruker Corp. 86 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Bruker Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BRKR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $80 over the next 12 months.
Bruker Corp. returned +52.9% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Bruker Corp. is a scientific instruments and analytical solutions company that provides technologies for life science, materials research, and diagnostic applications.
The most recent item we track (Zacks Investment Research, 8 Oct 2026): "Bruker Gains 66.3% in a Year: What's Driving the Rally?". Bruker shares gained 66.3% over a year, supported by strong demand in mass spectrometry and biopharma, despite restructuring challenges and currency headwinds.
Bruker Corp. is a scientific instruments and analytical solutions company that provides technologies for life science, materials research, and diagnostic applications. The company develops, manufactures, and distributes high-performance tools used to study matter at microscopic, molecular, and cellular levels, supporting research and testing across academic, clinical, industrial, and government settings. Its product portfolio includes magnetic resonance, mass spectrometry, X-ray, microscopy, metrology, chromatography, and molecular spectroscopy systems, along with specialized diagnostic and microbiology solutions. Bruker serves customers in biopharmaceuticals, in-vitro diagnostics, nanotechnology, semiconductor process control, and applied markets, making it an important supplier of advanced measurement and detection technologies in the global scientific equipment market.
CEO Dr. Frank H. Laukien Ph.D. · 11,085 employees · United States · https://www.bruker.com
